{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:06Z","timestamp":1790802426615,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,5]]},"DOI":"10.1016\/j.vhri.2026.102134","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:39:23Z","timestamp":1790599163000},"page":"102134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Budget Impact Analysis of System-Level Costs Associated With Topical Janus Kinase Inhibitor Therapies for Moderate Atopic Dermatitis in Germany"],"prefix":"10.1016","volume":"59","author":[{"given":"Svenja","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Broekmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Plommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"B\u00f6hme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10478","key":"10.1016\/j.vhri.2026.102134_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2026.102134_bib2","series-title":"Atopische dermatitis (AD) [neurodermitis; atopisches Ekzem]","author":"Werfel","year":"2023"},{"key":"10.1016\/j.vhri.2026.102134_bib3","author":"Werfel"},{"issue":"12","key":"10.1016\/j.vhri.2026.102134_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00105-005-0953-2","article-title":"Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland","volume":"56","author":"Ehlken","year":"2005","journal-title":"Hautarzt"},{"issue":"Suppl 7","key":"10.1016\/j.vhri.2026.102134_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.18168","article-title":"Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe","volume":"36","author":"Augustin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.vhri.2026.102134_bib6","first-page":"1416","article-title":"The direct and indirect costs of adult atopic dermatitis","volume":"27","author":"Manjelievskaia","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2026.102134_bib7","first-page":"13","article-title":"The economic and social burden of atopic dermatitis in Italy: a cost-of-illness analysis","volume":"17","author":"Antonini","year":"2024","journal-title":"GIHTAD"},{"key":"10.1016\/j.vhri.2026.102134_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1531042","article-title":"The economic burden of atopic dermatitis in Romania: a broad perspective","volume":"12","author":"Nicolescu","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.vhri.2026.102134_bib9","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.4556","article-title":"Economic burden of atopic dermatitis in Taiwan","volume":"103","author":"Lee","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.vhri.2026.102134_bib10","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European guideline (EuroGuiDerm) on atopic eczema: living update","volume":"39","author":"Wollenberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.vhri.2026.102134_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.10.908","article-title":"EE628 Systemic therapy of atopic dermatitis in Germany: real-world data on care structures and economic implications in a retrospective longitudinal study","volume":"27","author":"Kraska","year":"2024","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2026.102134_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of Ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.vhri.2026.102134_bib16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s13555-024-01219-8","article-title":"Ruxolitinib cream in adolescents\/adults with atopic dermatitis meeting severity thresholds for systemic therapy: exploratory analysis of pooled results from two phase 3 studies","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.vhri.2026.102134_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/CEOR.S506043","article-title":"Atopic dermatitis treatments before and after initiation of ruxolitinib cream: 6-month follow-up analysis of a US payer claims database","volume":"17","author":"Liu","year":"2025","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2026.102134_bib19","article-title":"Ruxolitinib cream improves atopic dermatitis pain, anxiety and depression over 52 weeks","author":"Kunzmann","year":"2022","journal-title":"HCPLive"},{"issue":"1","key":"10.1016\/j.vhri.2026.102134_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.102134_bib22","series-title":"Germany Atopic Dermatitis Therapeutics Market Analysis. Insights10","year":"2024"},{"key":"10.1016\/j.vhri.2026.102134_bib23","author":"Yadav"},{"issue":"8","key":"10.1016\/j.vhri.2026.102134_bib25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13555-022-00777-z","article-title":"Burden of moderate to severe atopic dermatitis in adults from France, Italy, and the UK: patient-reported outcomes and treatment patterns","volume":"12","author":"Kleyn","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.vhri.2026.102134_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.23736\/S2784-8671.22.07179-1","article-title":"The effects of dupilumab treatment on general health-related work productivity of adult atopic patients","volume":"157","author":"Napolitano","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.vhri.2026.102134_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","article-title":"Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD Study","volume":"158","author":"Strober","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.vhri.2026.102134_bib28","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3886","article-title":"Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay Registry","volume":"101","author":"Ari\u00ebns","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.vhri.2026.102134_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.09.1244","article-title":"EPH203 The prevalence of alopecia areata in Germany: results of an insurance claims database analysis","volume":"26","author":"Augustin","year":"2023","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2026.102134_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.17683","article-title":"Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.vhri.2026.102134_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/da.22711","article-title":"Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries","volume":"35","author":"Alonso","year":"2018","journal-title":"Depress Anxiety"},{"issue":"1-3","key":"10.1016\/j.vhri.2026.102134_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jad.2012.10.024","article-title":"The cost of depression\u2014a cost analysis from a large database","volume":"147","author":"Kleine-Budde","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.vhri.2026.102134_bib36","series-title":"Gesundheitswesen. Abrocitinib (Atopische Dermatitis bei Jugendlichen \u2265 12 Jahre); Nutzenbewertung Gem\u00e4\u00df \u00a7 35a SGB V. IQWiG","year":"2024"},{"key":"10.1016\/j.vhri.2026.102134_bib37","series-title":"Nutzenbewertungsverfahren zum Wirkstoff tralokinumab (atopische Dermatitis)","year":"2021"},{"key":"10.1016\/j.vhri.2026.102134_bib39","series-title":"Nutzenbewertungsverfahren zum Wirkstoff upadacitinib (Neues Anwendungsgebiet: Riesenzellarteriitis)","year":"2022"},{"key":"10.1016\/j.vhri.2026.102134_bib40","series-title":"Nutzenbewertungsverfahren zum Wirkstoff lebrikizumab (Neues Anwendungsgebiet: atopische Dermatitis, \u2265 12 Jahre)","author":"Hermal","year":"2021"},{"key":"10.1016\/j.vhri.2026.102134_bib42","series-title":"Nutzenbewertungsverfahren zum Wirkstoff abrocitinib (atopische Dermatitis)","year":"2022"},{"issue":"6","key":"10.1016\/j.vhri.2026.102134_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.vhri.2026.102134_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2340\/00015555-3102","article-title":"Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries","volume":"99","author":"Zink","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.vhri.2026.102134_bib46","series-title":"Poster presented at: ISPOR Europe: Barcelona, Spain","article-title":"EE628 Systemic therapy of atopic dermatitis in Germany: real-world data on care structures and economic implications in a retrospective longitudinal study","author":"Flume","year":"2024"},{"key":"10.1016\/j.vhri.2026.102134_bib47","series-title":"Daten zum Gesundheitswesen: Versicherte","year":"2026"},{"issue":"11","key":"10.1016\/j.vhri.2026.102134_bib48","first-page":"1","article-title":"Atopische dermatitis\u2014ein praxisnaher behandlungspfad","volume":"68","author":"Kurzen","year":"2025","journal-title":"Dtsch Dermatologe"},{"key":"10.1016\/j.vhri.2026.102134_bib49","author":"Leitfaden"},{"issue":"8","key":"10.1016\/j.vhri.2026.102134_bib50","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s13555-022-00773-3","article-title":"Treatment patterns and healthcare resource utilization among patients with atopic dermatitis: a retrospective cohort study using German health claims data","volume":"12","author":"Schild","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.vhri.2026.102134_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/CLEP.S315888","article-title":"Prevalence and medications of atopic dermatitis in Germany: claims data analysis","volume":"13","author":"Hagenstr\u00f6m","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.vhri.2026.102134_bib52","series-title":"Treatment patterns, inadequate disease control and burden\/unmet need among adult patients with moderate-to-severe atopic dermatitis: results from the Adelphi Real World Disease Specific Programme","author":"Silverberg","year":"2025"},{"issue":"5","key":"10.1016\/j.vhri.2026.102134_bib53","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1080\/09546634.2022.2038361","article-title":"Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)","volume":"33","author":"de Bruin-Weller","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.vhri.2026.102134_bib55","series-title":"Update on FDA Review of Ruxolitinib Cream (Opzelura\u00ae) for Children Ages 2-11 With Atopic Dermatitis","year":"2025"},{"issue":"1","key":"10.1016\/j.vhri.2026.102134_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33590\/emjdermatol\/URPI2929","article-title":"Atopic dermatitis at the European Academy of Dermatology and Venereology 2025: updates and insights","volume":"13","author":"Kirsop","year":"2025","journal-title":"EMJ Dermatol"},{"issue":"suppl 7","key":"10.1016\/j.vhri.2026.102134_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.19390","article-title":"The burden of skin disease in Europe","volume":"37","author":"Trakatelli","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vhri.2026.102134_bib59","author":"Wildenrath"},{"key":"10.1016\/j.vhri.2026.102134_bib60","author":"Liu"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:42:19Z","timestamp":1790800939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926005492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,5]]},"references-count":46,"alternative-id":["S2212109926005492"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102134","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget Impact Analysis of System-Level Costs Associated With Topical Janus Kinase Inhibitor Therapies for Moderate Atopic Dermatitis in Germany","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102134"}}